Sandy Wong, MD, Discusses Phase I Trial of Alnuctamab in Relapsed/Refractory Multiple Myeloma
By Cecilia Brown, Sandy Wong, MD - Last Updated: January 11, 2023Sandy Wong, MD, of the University of California San Francisco, discusses results from a phase I first-in-human study of alnuctamab in patients with relapsed/refractory multiple myeloma. Dr. Wong and colleagues presented the research at the 2022 American Society of Hematology Annual Meeting.
Advertisement
Post Tags:Myeloma ASH 22
Advertisement
Related Posts
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Stephen M. Ansell, MD, PhD, explains the importance of making an accurate diagnosis of Hodgkin lymphoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.